ACKNOWLEDGEMENTS

This report was prepared by Janet Li and Rosalind Sexton on behalf of the ACT Cancer Registry. The authors would like to acknowledge the contributions of the ACT BreastScreen Program and the ACT and SE NSW Breast Cancer Treatment Group in providing input into sections of this report.

The Staff of the ACT Cancer Registry and the Epidemiology Branch would like to acknowledge the contribution of staff in hospitals, nursing homes and pathology laboratories throughout the ACT for their continued support in notifying cancer cases.

The majority of deaths data contained in this publication have been obtained from the ACT Registrar of Births, Deaths, and Marriages. The Australian Bureau of Statistics supplies population and demographic data and coded death data. Our thanks are extended to the Australian Institute of Health and Welfare for assistance with matching of death data and duplicate registrations.

Special thanks to all other state and territory Registries and to the Australasian Association of Cancer Registries for their support. We would like to especially thank the staff of the New South Wales Central Cancer Registry for their continued assistance.

ISSN 1325-1090
# TABLE OF CONTENTS

EXECUTIVE SUMMARY ........................................................................................................................ 6

1. INTRODUCTION ........................................................................................................................................ 7

2. INCIDENCE ............................................................................................................................................ 8
   2.1. Trends in incidence .......................................................................................................................... 11
   2.2. Interstate comparisons .................................................................................................................... 12
   2.3. International comparisons ............................................................................................................. 12

3. MORTALITY ........................................................................................................................................ 13
   3.1. Trends in mortality .......................................................................................................................... 15
   3.2. Interstate comparison ..................................................................................................................... 16
   3.3. International comparison .............................................................................................................. 17

4. SURVIVAL ........................................................................................................................................... 18
   4.1. Relative survival estimates ............................................................................................................... 18
   4.2. Interstate comparison ..................................................................................................................... 20
   4.3. International comparison .............................................................................................................. 21

5. SCREENING ....................................................................................................................................... 22
   5.1. Participation ....................................................................................................................................... 22
   5.2. Detection of all-size and small invasive cancers ........................................................................... 23
   5.3. Interval cancer rate .......................................................................................................................... 25
   5.4. Program sensitivity .......................................................................................................................... 26
   5.5. Private screening ............................................................................................................................. 29

6. RISK FACTORS ................................................................................................................................. 30
   6.1. Profile of breast cancer risk factors in ACT women ........................................................................ 31

7. TREATMENT ....................................................................................................................................... 33
   7.1. The ACT and SE NSW Breast Cancer Treatment Group ............................................................ 33
   7.2. Characteristics of breast cancer patients ...................................................................................... 33
   7.3. Method of detection and tumour size ............................................................................................ 34
   7.4. Surgical and adjuvant treatment ................................................................................................... 35

8. STATISTICAL DEFINITIONS AND METHODOLOGY ................................................................... 37

9. REFERENCES ....................................................................................................................................... 39
FIGURES

Figure 1: Anatomy of the female breast ................................................................. 7
Figure 2: Proportion of new cases of cancers in women by cancer type, all ages, ACT, 2002-06 ................................................................. 8
Figure 3: Incidence of female breast cancer by age, ACT, 1995-2006 ....................... 9
Figure 4: Proportion of female breast cancer of all cancer types in females by age, ACT, 1995-2006 ................................................................. 9
Figure 5: Median age at diagnosis for selected cancers, females, ACT, 2002-06 ........................................................................ 10
Figure 6: Incidence of female breast cancer by age & spread, ACT, 1995-2006 ................ 10
Figure 7: Trends in incidence of female breast cancer, age-standardised rates by year, ACT & Australia, 1985-2006 ........................................... 11
Figure 8: Incidence of female breast cancer by age and 5-year cohorts, ACT, 1995-2006 ................................................................. 12
Figure 9: Average annual incidence (age-standardised) of female breast cancer by state & territory, Australia, 2002-06 ................................................................. 12
Figure 10: Common causes of death for ACT females, all ages, 2002-06 .................... 13
Figure 11: Common causes of cancer related death in ACT women, all ages, 2002-06 .... 14
Figure 12: Median age at death for selected cancers, females, ACT, 2002-06 ................ 14
Figure 13: Mortality of breast cancer in women by age, ACT, 1995-2006 ..................... 15
Figure 14: Trends in mortality of female breast cancer, age-standardised rates, ACT & Australia, 1982-2006 ................................................................. 15
Figure 15: Mortality of female breast cancer by age and 5-year cohorts, ACT, 1995-2006 ................................................................. 16
Figure 16: Average annual mortality rates of female breast cancer by states, territories, & Australia, 2002-06 ................................................................. 16
Figure 17: Age-standardised incidence & mortality of female breast cancer, selected countries/regions, 2002 ................................................................. 17
Figure 18: Survival by age-group, female breast cancer, ACT, 2000-04 ......................... 19
Figure 19: Survival by stage, female breast cancer, ACT, 2000-04 .............................. 19
Figure 20: Survival by period, female breast cancer, ACT, 1995-2004 ......................... 20
Figure 21: Five-year relative survival of female breast cancer, states, territories & Australia ................................................................. 20
Figure 22: Five-year relative survival of female breast cancer, selected countries .......... 21
Figure 23: Participation rates for BreastScreen Program, women aged 50-69 years, ACT & Australia, 1996-2006 ................................................................. 22
Figure 24: Small (<15mm) invasive breast cancer detection rate in women aged 50-69 years, first screening round, ACT & Australia, 1998-2006 ................................................ 23
Figure 25: All-size invasive breast cancer detection rate in women aged 50-69 years, first screening rounds, ACT & Australia, 1998-2006 ................................................ 24
Figure 26: All-size invasive breast cancer detection rate in women aged 50-69 years, subsequent screening rounds, 1998-2006 ................................................ 25
Figure 27: Interval cancer rate for women aged 50-69 years, first screening round, 0-12 months follow up, ACT & Australia, 1996-2003 ................................................ 26
Figure 28: Program sensitivity for women aged 50-69 years, first screening round, 0-12 months follow up, ACT & Australia, 1996-2003 ................................................ 27
Figure 29: Program sensitivity for women aged 50-69 years, first screening round, 0-24 months follow up, ACT & Australia, 1996-2003 ................................................................. 27
Figure 30: Program sensitivity for women aged 50-69 years, subsequent screening round, 0-12 months follow up, ACT & Australia, 1996-2003 ................................................................. 28
Figure 31: Program sensitivity for women aged 50-69 years, subsequent screening round, 0-24 months follow up, ACT & Australia, 1996-2003 ................................................................. 28
Figure 32: Median maternal age at first full-term pregnancy, ACT & Australia, 1997-2005 ................................................................. 31
Figure 33: Women who have not given birth, 45 years and over, by percentage, ACT & Australia, 2000 .................................................................................................................. 31
Figure 34: Index of relative advantage & disadvantage, by state & territory, 2006 ................................................................. 32
Figure 35: Treated breast cancer cases included in the Breast Cancer Treatment Quality Assurance Project, number, ACT & surrounding SE NSW region, 1 Jul 1997 to 30 June 2008 ......................................................................................................................... 33
Figure 36: Breast cancer patients by method of detection & tumour size, ACT & SE NSW region, 1997-2008 ......................................................................................................................... 34
Figure 37: Types of treatment received by breast cancer patients, ACT & SE NSW region, 1997-2008 ......................................................................................................................... 36

TABLES
Table 1: Survival by years after diagnosis, age-group & stage, female breast cancer, ACT, 1995-2004 ......................................................................................................................... 18
Table 2: Five-year relative survival & details for estimation for female breast cancer, states, territories & Australia ......................................................................................................................... 21
Table 3: Factors that increase the relative risk for female breast cancer ......................................................................................................................... 30
Table 4: Characteristics of breast cancer patients, ACT & SE NSW region, 1997-2008 ......................................................................................................................... 34
Executive summary

Breast cancer is the most common cause of cancer in women and the highest cause of cancer related death in women in both the ACT and Australia. In the ACT, breast cancer represented 34.5% of all cancers and accounted for 5% of all deaths, in women over the 5-year period 2002-06.

Incidences:
Over the five-year period 2002-06, the crude incidence was 123.5 cases per 100,000 women representing an average of 205 new cases per year in the ACT. Yearly rates have not changed significantly since 2002.

In 2002-06, one in 10 women in the ACT developed breast cancer before 75 years of age and one in seven women before 85 years.

Since 2000, rates of breast cancer in the ACT have been consistently higher than national rates, although this difference was only statistically significant in the years 2000 and 2004.

Risk factors:
Women in the ACT have a higher prevalence of several known risk factors for breast cancer compared with the Australian population. These include being older at the birth of their first child, a higher proportion of women who have never given birth, higher socio-economic status, and a higher proportion of alcohol consumption at regular or risky levels.

Mortality:
An average of 35 women in the ACT die each year from a breast cancer related illness. In 2002-06, the crude mortality rate was 21 deaths per 100,000 females. Mortality rates have remained stable over time and are similar to rates in the rest of the Australian population.

The risk of dying from breast cancer in the ACT was 1 in 61 females before the age of 75 years and 1 in 41 females before the age of 85 years.

Survival:
The five-year survival for female breast cancer was 91 per cent. Survival from breast cancer has significantly improved. Over the ten years between 1995 and 2004, survival has increased from 87% in 1995-1999 to 92% in 2000-04. ACT has one of the highest survival rates of all jurisdictions.

Consistent with expectations women diagnosed with more advanced breast cancer experienced a lower survival (localised spread: 98%; distant metastasis: 40%).

Screening:
Between 1996-2006, an average of 55-60 per cent of women in the targeted age-group (50-69 years) participated in the ACT National BreastScreen Program. This does not account for women who chose to be screened in the private sector.

The detection rate of the ACT BreastScreen Program for small or all-size invasive breast cancer in the target women was higher than the aims for the National Accreditation Standards and higher than the Australian detection rate. During 1996-2003, the ACT BreastScreen Program had high program sensitivity (90-95%) indicating that few cancers are missed by screening.

Most of the small size invasive breast cancers were detected by the BreastScreen Program (50%), other mammogram screening (16%) or patient self-examination (29%).

Treatment:
During 1997-2008, of the breast cancer patients who had invasive cancer and who underwent surgery in the ACT and SE NSW region, about half had a mastectomy (53%) and the rest had breast conserving surgery (47%). Over 90 per cent of these patients received adjuvant treatment.
1. Introduction

Breast cancer is the most common cause of cancer and cancer related death in women in both the ACT and Australia.\textsuperscript{1,2} Breast cancer is rare in young women under the age of 30, increasing in incidence with age. When breast cancer occurs in young women, it tends to be more aggressive and has a worse prognosis than when it occurs in older women.\textsuperscript{3-5}

The most common types of breast cancer begin either in the milk ducts (ductal carcinoma) or in the milk-producing glands (lobular carcinoma) (Figure 1).

Figure 1: Anatomy of the female breast


In situ breast cancer

In situ (non-invasive) breast cancer refers to cancer in which the cells have remained within their place of origin - they haven’t spread to breast tissue around the duct or lobule. The most common type of non-invasive breast cancer is ductal carcinoma in situ (DCIS), which is confined to the lining of the milk ducts with no spread through the duct walls into surrounding breast tissue. With appropriate treatment, DCIS has an excellent prognosis.

Invasive breast cancer

Invasive (infiltrating) breast cancers spread outside the membrane that lines a duct or lobule, invading the surrounding tissues. The cancer cells can then travel to other parts of the body, such as the lymph nodes.

\textbf{Invasive ductal carcinoma (IDC)}

IDC accounts for eight out of ten invasive breast cancers.\textsuperscript{7} The cancer cells form in the lining of the milk duct, then break through the ductal wall and invade nearby breast tissue. The cancer cells may remain localized, staying near the site of origin, or spread (metastasize) throughout the body, carried by bloodstream or the lymphatic system.

\textbf{Invasive lobular carcinoma (ILC)}

Although less common than IDC, this type of breast cancer invades in a similar way, starting in the milk-producing lobules and then breaking into the surrounding breast tissue. ILC can also spread to more distant parts of the body.

This report examines trends, incidence, mortality, survival, risk factors, screening and treatment of invasive female breast cancer in the ACT for the period of 1995-2006. The report provides a detailed supplement to Health Series Number 42, Cancer in the ACT 1998-2004.\textsuperscript{2} Note due to the small numbers of breast cancer cases in the ACT, data are often reported over five-year periods.

Definitions and methods to aid with the interpretation of information in this report are available in Chapter 9 e.g. crude rate (CR) and age-standardised rate (ASR). Health policy makers may be interested in the crude rate for planning purposes because it reflects the actual unadjusted rate of the ACT. For readers who want to compare jurisdictional rates, the age-standardised rate is appropriate.
2. Incidence

Breast cancer was the most common cancer among women in the ACT accounting for 34.5% of cancers in 2002-06. Over this period the annual crude incidence was 123.5 cases per 100,000 women representing an average of 205 new cases per year in the ACT. In 2002-06, one in 10 women in the ACT developed breast cancer before 75 years of age and one in seven women before 85 years.

The ACT age-standardised rate for female breast cancer was 129.6 cases per 100,000 women in 2002-06. This rate was calculated using the Australian 2001 Standard Population and can be used for comparing the ACT with other jurisdictions.

While breast cancer accounted for one third of all cancers in women (Figure 2); the proportion is higher in older women. For women aged 40-59 years breast cancer accounted for 50% of all cancers.

Figure 2: Proportion of new cases of cancers in women by cancer type, all ages, ACT, 2002-06

Source: ACT Cancer Registry.
Breast cancer is rare among young women. Over the period 1995-2006, less than one per cent of all breast cancer cases occurred in women under the age of 30 years. The incidence of breast cancer rose steadily with age, peaking in the 65-69 year age-group (Figure 3).

**Figure 3:** Incidence of female breast cancer by age, ACT, 1995-2006

Breast cancer as a proportion of all cancers in women decreased with age from 55 years of age (Figure 4).

**Figure 4:** Proportion of female breast cancer of all cancer types in females by age, ACT, 1995-2006

Between 2002-06, the median age at diagnosis was 57 years, two years younger than the median age in Australia. Compared to other major cancers in women, breast cancer had the fourth youngest median age at diagnosis (Figure 5).
The localised and metastatic spread of breast cancer at diagnosis varied with age.

Younger women aged 30-49 years have similar incidence of regional spread of disease and localised spread of disease (Figure 6). This indicates that when detected, the disease is equally likely to have spread to the regional lymph nodes as it is to be found only in the breast.

In women over 50 years of age, the incidence of regional spread of disease is much lower than the incidence of localised spread of disease. This is probably due to early detection and diagnosis of breast cancer through screening programs, resulting in a more localised stage at diagnosis.
2.1. Trends in incidence

The incidence of breast cancer in the ACT has increased since 1989 although remaining stable since 2002. The average annual percentage change (AAPC) of the age-standardised incidence increased significantly at a rate of 2.7 per cent per year from 1989 to 2002.

The upward trend in the years up to 2002 may reflect the introduction of the BreastScreen Program in 1993 for women aged 50-69 years and the greater sensitivity of diagnostic methods, both leading to earlier breast cancer detection. The mandatory notification of cancers in 1994 has also contributed to an increase in notifications from that year. These factors coupled with changes in known risk factors for breast cancer would contribute to the observed trends.

Since 2002, the average annual percentage change (AAPC) of the age-standardised incidence rate of breast cancer has not changed significantly. This observation coincides with a reduction in the use of hormone replacement therapy along with a levelling of participation rates in the BreastScreen Program over recent years.

The incidence of breast cancer in the ACT fluctuates from year to year. These fluctuations reflect the low numbers of cases in the ACT, where small changes in the number of cases can result in large changes in rates (Figure 7). Caution should always be used when interpreting these rates and comparing with other jurisdictional rates.

Although the annual incidence of breast cancer has been consistently higher than the national incidence since 2000 (Figure 7), a statistically significant difference was only observed in the years 2000 and 2004.

**Figure 7: Trends in incidence of female breast cancer, age-standardised rates by year, ACT & Australia, 1985-2006**

Breast cancer incidence increased significantly in the 65-69 year age-group (part of the target group of the BreastScreen Program) and in women over 75 years, over the two five-year periods 1995-1999 and 2002-2006 (Figure 8).
2.2. Interstate comparisons

Over the five-year period 2002-06, the ACT had the highest annual average incidence of female breast cancer compared to other states and territory (Figure 9). The age-standardised incidence in the ACT was significantly higher than the national rate over this period.

Figure 9: Average annual incidence (age-standardised) of female breast cancer by state & territory, Australia, 2002-06

Note: Rates age-standardised to the Australian Standard Population 2001 (95% Confidence Intervals).

2.3. International comparisons

There is a large variation in the incidence of female breast cancer around the world. In general, developed countries have a higher incidence rate than developing countries. In 2002, Australia was among those countries with the highest incidence of breast cancer. Countries with the lowest incidence of breast cancer include China, Middle Africa and South America. Westernized countries in Asia such as Japan, Hong Kong and Singapore had a relatively higher incidence than other less developed Asian countries.
3. Mortality

Over the period 2002-06, breast cancer was the fifth most common cause of death (Figure 10) and the most common cause of cancer related death among women in the ACT (Figure 11). Over this period there was an average of 35 breast cancer related deaths each year in the ACT. The annual crude mortality rate was 21 deaths per 100,000 women. The risk of a woman dying from breast cancer in the ACT was one in 61 before the age of 75 years and one in 41 before the age of 85 years.

For comparative purposes the annual age-standardised mortality rate was 22.3 deaths per 100,000 women (standardised to the Australian 2001 Standard Population).

Breast cancer accounted for 18.6 per cent of cancer related deaths in ACT women over the 2002-06 period (Figure 11). The median age at death for females with breast cancer was 63 years, this was one of the youngest median ages of all cancer related deaths in women (Figure 12).

Figure 10: Common causes of death for ACT females, all ages, 2002-06

<table>
<thead>
<tr>
<th>Cause</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischaemic heart disease</td>
<td>12.5%</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>11.5%</td>
</tr>
<tr>
<td>Other forms of heart disease</td>
<td>5.9%</td>
</tr>
<tr>
<td>Dementia &amp; related disorders</td>
<td>5.7%</td>
</tr>
<tr>
<td>COPD</td>
<td>4.1%</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>5.0%</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>1.7%</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>3.7%</td>
</tr>
<tr>
<td>Influenza and pneumonia</td>
<td>1.8%</td>
</tr>
<tr>
<td>Diabetes</td>
<td>2.5%</td>
</tr>
<tr>
<td>All other causes combined</td>
<td>45.6%</td>
</tr>
</tbody>
</table>


Note: All other causes combined are the remainder of causes of death combined after counting the top ten causes of death.
Figure 11: Common causes of cancer related death in ACT women, all ages, 2002-06

Breast 19%
Colorectal 15%
Lung 14%
Unknown site 10%
Ovary 6%
Pancreas 5%
Non-Hodgkin's lymphoma 5%
Stomach 4%
Brain 4%
All leukaemias 4%
Kidney 4%

Source: ACT Cancer Registry.

Figure 12: Median age at death for selected cancers, females, ACT, 2002-06

Source: ACT Cancer Registry.
Note: Histogram bar shows median age with interquartile range (25% and 75%) indicated by the bolded H bar.
Most (84%) breast cancer related deaths in ACT women occurred among women aged 45 years or older. The number of deaths peaked in the 50-54 years age-group although mortality rates steadily increased with age (Figure 13).

Figure 13: Mortality of breast cancer in women by age, ACT, 1995-2006

3.1. Trends in mortality

The mortality rate of breast cancer in women in the ACT has not changed significantly since 1982 (Figure 14), although there appears to be a downward trend in breast cancer mortality rates both nationally and in the ACT particularly since 1995 post the introduction of the BreastScreen Program in 1993.

The fluctuations in the ACT rates are again due to small numbers with slight changes in numbers result in large fluctuations in rates. Although the ACT appeared to have a slightly higher mortality rate than the rest of the country over most of the period 1982-2006 this was not statistically significant other than in 1991.

Figure 14: Trends in mortality of female breast cancer, age-standardised rates, ACT & Australia, 1982-2006

Source: ACT Cancer Registry.
Mortality as a result of breast cancer decreased significantly in women over 55 years of age, between the two five-year periods 1995-1999 and 2002-2006 (Figure 15).

**Figure 15: Mortality of female breast cancer by age and 5-year cohorts, ACT, 1995-2006**

![Figure 15: Mortality of female breast cancer by age and 5-year cohorts, ACT, 1995-2006](image)

Source: ACT Cancer Registry.

3.2. Interstate comparison

Over the period 2002-06, rates of breast cancer related deaths in ACT women were similar to rates nationally (ACT: 22.3 deaths per 100,000 population; Australia: 23.8 deaths per 100,000 population) (Figure 16).

**Figure 16: Average annual mortality rates of female breast cancer by states, territories, & Australia, 2002-06**

![Figure 16: Average annual mortality rates of female breast cancer by states, territories, & Australia, 2002-06](image)

Source: ACT data from the ACT Cancer Registry; Australian and other jurisdictional data from the AIHW National Mortality Database extracted in October 2009.

Note: Rates age-standardised to the 2001 Australian Standard Population.
3.3. International comparison

The differences in mortality rates for female breast cancer worldwide are less notable than for incidence. In 2002, Australia’s age-standardised mortality rate (19.4 deaths per 100,000 population) for female breast cancer was similar to other developed countries. Australia ranked as having the second lowest mortality to incidence ratio (0.23) next to Northern America (0.19) (Figure 17).

In general, more affluent countries tend to have higher incidence of breast cancer, but due to better diagnosis and treatment they have better survival rates than less affluent countries. These patterns contribute to the low variation in mortality rates around the world.

**Figure 17: Age-standardised incidence & mortality of female breast cancer, selected countries/regions, 2002**


Note: GLOBOCAN 2002 presents estimates for the year 2002. However, although the populations of different countries are those estimated for the middle of 2002, the disease rates are not those for the year 2002, but from the most recent data available, generally 2-5 years earlier.
4. Survival

Relative survival ratios were calculated using the period method to measure breast cancer survival in the ACT. This survival ratio describes the proportion of the observed survival rate to expected survival rate, expressed as a percentage.

The observed survival rate refers to female breast cancer patients who would have survived to a certain time, usually five years for cancer, if the cancer they had was the only cause of death in the patient population. The expected survival rate refers to the expected rate of a group of people in the general population similar to the patient group with respect to race, age, sex and calendar period of observation.

4.1. Relative survival estimates

Based on data from 1995 to 2004 the five-year survival for women with breast cancer was 91% (Table 1). Localised disease had a substantially higher survival ratio (98%) compared to when the disease had spread regionally at the time of diagnosis (88%). The five-year survival ratio in more recent years (2000-04) was significantly higher than in the preceding years 1995-1999.

Table 1: Survival by years after diagnosis, age-group & stage, female breast cancer, ACT, 1995-2004

<table>
<thead>
<tr>
<th>Years after diagnosis</th>
<th>Survival (%)</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>99</td>
<td>(97-99)</td>
</tr>
<tr>
<td>2</td>
<td>96</td>
<td>(94-97)</td>
</tr>
<tr>
<td>3</td>
<td>94</td>
<td>(92-95)</td>
</tr>
<tr>
<td>4</td>
<td>93</td>
<td>(91-95)</td>
</tr>
<tr>
<td>5</td>
<td>91</td>
<td>(89-93)</td>
</tr>
</tbody>
</table>

By subgroup

<table>
<thead>
<tr>
<th>Number of cases</th>
<th>Number of deaths</th>
<th>5-year survival (%)</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cases</td>
<td>1078</td>
<td>116</td>
<td>91</td>
</tr>
</tbody>
</table>

Age at diagnosis

| 15-44 | 161 | 12 | 92 | (86-95) |
| 45-59 | 496 | 36 | 92 | (89-95) |
| 60-74 | 277 | 32 | 90 | (85-95) |
| 75+   | 144 | 36 | 91 | (78-100) |

Stage

| Localised | 570 | 34 | 98 | (95-100) |
| Regional  | 379 | 39 | 88 | (84-92)  |
| Distant   | 44  | 19 | 40 | (19-60)  |
| Unknown   | 85  | 24 | 73 | (60-85)  |

Selected period

| 1995-1999 | 87 | (84-89) |
| 2000-04   | 92 | (89-94) |

Source: ACT Cancer Registry.
Age at diagnosis:
There was little difference in five-year survival among age-groups other than women over 75 years showed lower survival up to 4 years after diagnosis (Figure 18).

Figure 18: Survival by age-group, female breast cancer, ACT, 2000-04

Stage:
Relative survival decreased significantly over five years when cases had distant spread at the time of diagnosis (Figure 19).

Figure 19: Survival by stage, female breast cancer, ACT, 2000-04
Time trends:
Survival significantly improved over the ten-year period between 1995 and 2004, ranging from 87% (95% CI: 84-89%) in 1995-99 to 92% (95% CI: 89-94%) in 2000-04 (Figure 20).

Figure 20: Survival by period, female breast cancer, ACT, 1995-2004

Source: ACT Cancer Registry.

4.2. Interstate comparison
The five-year survival ratio in the ACT was higher than published ratios for Australia and Victoria (Figure 21). Comparisons with other jurisdictions should be interpreted with caution because not all the registries used the same method and period of diagnosis to estimate the relative survival ratio (refer Table 2 for different methodologies used by jurisdictions).

Figure 21: Five-year relative survival of female breast cancer, states, territories & Australia

Sources: Australian Institute of Health and Welfare14, Western Australian Cancer Registry15, ACT Cancer Registry, Cancer Institute NSW16, the Cancer Council, Victoria17, Northern Territory Cancer Registry18, Queensland Health and Queensland Cancer Fund19, South Australia Cancer Registry20.
Table 2: Five-year relative survival & details for estimation for female breast cancer, states, territories & Australia

<table>
<thead>
<tr>
<th>State/Territory</th>
<th>5-year relative survival (%)</th>
<th>Period of diagnosis</th>
<th>Method</th>
<th>Ages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>87.8</td>
<td>1998-2004</td>
<td>period</td>
<td>All</td>
</tr>
<tr>
<td>WA</td>
<td>91.1</td>
<td>1998-2002</td>
<td>cohort</td>
<td>15+</td>
</tr>
<tr>
<td>ACT</td>
<td>91.0</td>
<td>1995-2004</td>
<td>period</td>
<td>15-89</td>
</tr>
<tr>
<td>NSW</td>
<td>88.0</td>
<td>1999-2003</td>
<td>cohort</td>
<td>15-89</td>
</tr>
<tr>
<td>VIC</td>
<td>87.0</td>
<td>1990-2004</td>
<td>period</td>
<td>All</td>
</tr>
<tr>
<td>NT (Non-indigenous)</td>
<td>87.0</td>
<td>1991-2001</td>
<td>cohort</td>
<td>Not stated</td>
</tr>
<tr>
<td>QLD</td>
<td>86.9</td>
<td>1996-2000</td>
<td>cohort</td>
<td>15-89</td>
</tr>
<tr>
<td>SA</td>
<td>85.0</td>
<td>1997-2003</td>
<td>cohort</td>
<td>All</td>
</tr>
<tr>
<td>NT (Indigenous)</td>
<td>56.0</td>
<td>1991-2001</td>
<td>cohort</td>
<td>Not stated</td>
</tr>
</tbody>
</table>

Sources: Australian Institute of Health and Welfare14, Western Australian Cancer Registry15, ACT Cancer Registry, Cancer Institute NSW16, the Cancer Council, Victoria17, Northern Territory Cancer Registry18, Queensland Health and Queensland Cancer Fund19, South Australia Cancer Registry20

4.3. International comparison

There is a large variation in the survival of female breast cancer around the world. Developed and more affluent countries in general had higher survival than less developed and less affluent countries. Australia had the third highest five-year survival (88%) next to USA (90.1%) and Iceland (93.4%) (Figure 22).

Figure 22: Five-year relative survival of female breast cancer, selected countries

Sources: Australian data from AIHW: Cancer survival and prevalence in Australia: cancers diagnosed from 1982 to 200414; All other data from Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data.21
5. Screening

As with other forms of cancer, early detection and timely treatment for breast cancer are associated with a favourable long-term prognosis. Mammography is used for the screening of breast cancer at an early stage where women are unlikely to have any symptoms.

In Australia, the National Program for Early Detection of Breast Cancer was established in 1991, and since 1994 has been called *BreastScreen Australia*. It was rolled out to the states and territories progressively and commenced in the ACT in 1993.

The program provides free biennial mammographic screening and follow-up of any suspicious lesions identified at screening to the point of diagnosis. It aims specifically at asymptomatic women aged 50-69 years of age, with a participation target of 70%. Women aged 40-49 years and 70 years and older may also attend for screening.

The indicators used to determine if the screening program is effective are:

- participation;
- detection of cancer;
- cancers that occur in between screening intervals; and
- sensitivity of the program to detect disease when it is present.

5.1. Participation

**The Participation Indicator**

The participation rate in the BreastScreen Australia program is calculated as the proportion of women aged 50-69 years who undergo mammography within a two-year period.

One of the objectives of the BreastScreen Australia Program is to achieve a 70 per cent participation rate in the national program by women in the target group.

The participation rate of ACT women was consistently between 55 and 60 per cent for most years during 1996-2006. ACT rates were higher than national rates between 1996 and 2000 and have remained similar to the national rates since 2000 (Figure 23). The target participation rate has not been achieved nationally or in the ACT.

**Figure 23: Participation rates for BreastScreen Program, women aged 50-69 years, ACT & Australia, 1996-2006**


Note: Rates reported with 95% Confidence Intervals, note small Confidence Intervals.
5.2. Detection of all-size and small invasive cancers

5.2.1. Detection of small invasive cancers

Small Invasive Cancer Detection Indicator

This indicator reports the rate of invasive breast cancer in women that are 15 mm or less in size detected at a BreastScreen Australia service.

This indicator is expressed as the number of women with small invasive cancer detected for every 10,000 women screened for the target age-group (50-69 years).

National Accreditation Standards provide a minimum indicator that needs to be attained to ensure the program has screened enough women to be able to detect those with disease.

ACT detection rates of small invasive breast cancer in women aged 50-69 years were all above the recommended standard, except for 2003 (Figure 24). The differences in detection rates between ACT and Australia were not statistically significant for any year during 1998-2006.

Figure 24: Small (<15mm) invasive breast cancer detection rate in women aged 50-69 years, first screening round, ACT & Australia, 1998-2006

Note: Definition of small invasive breast cancer prior to 2000 was size <10mm.
Rates reported with 95% Confidence Intervals
5.2.2. Detection of all size cancers

**All-size Cancer Detection Indicator**

This indicator reports the rate of invasive breast cancer of any size detected in women at a BreastScreen Australia service.

The indicator is expressed as the number of women with cancer detected for every 10,000 women screened for the target age-group (50-69 years). Indicators are reported for detection on the first mammography screen and subsequent screens.

National Accreditation Standards provide a minimum indicator that needs to be attained to ensure the program has screened enough women to be able to detect those with disease.

The National Accreditation Standards for the detection of all-size and small (≤ 15mm) invasive breast cancers require that:

- ≥50 per 10,000 women aged 50-69 years who attend for their first screen are diagnosed with invasive breast cancer.
- ≥35 per 10,000 women aged 50-69 years who attend for their second or subsequent screen are diagnosed with invasive breast cancer.
- ≥25 per 10,000 women aged 50-69 years who attend for their screening are diagnosed with small (≤ 15mm) invasive breast cancer.

The first screening round is a woman’s first visit to mammography screening service; a subsequent screening round means that she has been screened before.

**First screen**

The detection rate of all-size invasive breast cancer in women aged 50-69 years at the first screening round were above the recommended standard (≥50 per 10,000 women) for most years during 1998-2002 in the ACT. The exceptions were 2000 and 2002 (Figure 25). The difference in detection rates between the ACT and Australia were not statistically significant for any year during 1998-2006.

**Figure 25: All-size invasive breast cancer detection rate in women aged 50-69 years, first screening rounds, ACT & Australia, 1998-2006**


Note: Rates reported with 95% Confidence Intervals.
Second and subsequent screen

The detection rate of all-size invasive breast cancer in women aged 50-69 years at the subsequent screening rounds were above the recommended standard (≥35 per 10,000 women) in the ACT for most years during 1998-2006, the exception being 2005 (Figure 26).

The difference in detection rates between the ACT and Australia were not statistically significant for any year during 1998-2006.

**Figure 26: All-size invasive breast cancer detection rate in women aged 50-69 years, subsequent screening rounds, 1998-2006**

Note: Note rates reported with 95% Confidence Intervals.

5.3. Interval cancer rate

**Interval Cancer Rate Indicator**

This indicator reports on invasive breast cancer that developed between screening episodes. That is, a previous screen was negative and breast cancer was found before the next screen was due to occur.

The interval cancer rate is expressed per 10,000 women-years at risk.

A low-interval cancer rate is one measure of the effectiveness of the screening program.

The National Accreditation Standards for the detection of interval breast cancers require:

- <7.5 interval cancers per 10,000 women-years aged 50-69 years who attend for screening less than 12 months following a negative screening episode.

- The number per 10,000 women-years aged 50-69 years who attend screening and who are diagnosed with an invasive interval breast cancer in the period of 12-24 months following a negative screening episode.
First Screen, 0-12 months

First Screen, 0-12 months refers to detection of breast cancer within one year of a first screening mammography in which no disease was detected.

The interval cancer rate for women aged 50-69 years who attended for mammography less than 12 months following a negative screening episode at their first screening episode was lower than the recommended level (<7.5 per 10,000 women-years) in 1998, 1997-1999 and 2001-2003 (Figure 27).

Figure 27: Interval cancer rate for women aged 50-69 years, first screening round, 0-12 months follow up, ACT & Australia, 1996-2003

![Graph showing interval cancer rate for women aged 50-69 years, first screening round, 0-12 months follow up, ACT & Australia, 1996-2003.]

Note: Australian & ACT data after 2003 were not available at the time of writing of this report. Interval cancer rates were only reported by jurisdictional level, but not at national level for reports prior to 1998.

5.4. Program sensitivity

BreastScreen Program Sensitivity Indicator

Is the proportion of women who participate in the screening program who have invasive breast cancer. This includes those cancers detected at screening and in the interval.

A high sensitivity indicates that few cancers are missed.

Program sensitivity measures the ability of the BreastScreen Program to detect invasive breast cancers in women attending for screening.

Within one year of initial screen

At 0-12 months follow up of the first screening round, the ACT reached a program sensitivity of about 90 per cent for most years over the period 1996-2002. In 2001-03, the ACT’s program sensitivity increased to 95.8 per cent (Figure 28). There was no statistically significant difference between ACT and national rates.
Within two years of initial screen

At 0-24 months follow up of the first screening round, the ACT reached a program sensitivity of around 80 per cent during 1996-2002. In 2001-03, the ACT’s program sensitivity increased to above 85 per cent (Figure 29). There was no statistically significant difference between ACT and national rates.
Within one year of subsequent screens

At 0-12 months follow up of the subsequent screening round, the ACT had a program sensitivity of between 60-90 per cent over the period 1996-2003. This was comparable to available national data over the same period (Figure 30). There was no statistically significant difference between ACT and national rates.

**Figure 30: Program sensitivity for women aged 50-69 years, subsequent screening round, 0-12 months follow up, ACT & Australia, 1996-2003**

Note: Australian & ACT data after 2003 were not available at the time of writing of this report.

Within two years of subsequent screens

At 0-24 months follow up of the subsequent screening round, the ACT reached a program sensitivity of around 80-90 per cent during 1997-2003. There was no statistically significant difference between ACT and national rates (Figure 31).

**Figure 31: Program sensitivity for women aged 50-69 years, subsequent screening round, 0-24 months follow up, ACT & Australia, 1996-2003**

Note: Australian & ACT data after 2003 were not available at the time of writing of this report. Estimates were only reported by jurisdictional level, but not at national level for reports prior to 1998.
5.5. Private screening

ACT breast screening activities are not fully reflected in data from the publicly funded BreastScreen program. This is because a proportion of ACT women in the target group use private services for breast screening and these data are not captured in the statistics.

Due to the lack of information on private breast screening activities, it is difficult to estimate the proportion of women who may have been screened privately. Information collected by the Breast Cancer Treatment Group (BCTG) in the ACT and SE NSW suggests that approximately 19 per cent of breast cancers detected through screening were detected in the private sector.\textsuperscript{22}
6. Risk factors

Many of the known risk factors for breast cancer in women are not easily modifiable. These include: age, family history, genetic factors (BRCA1 and BRCA2), age at first full-term pregnancy, early menarche, late menopause, and breast density. However, other risk factors are modifiable such as: physical activity, alcohol consumption, use of oral contraceptives, use of post-menopausal hormones and postmenopausal obesity. Socio-economic status is indirectly linked to breast cancer incidence due to the correlation with reproductive behaviour.

A list of relative risks associated with known risk factors derived from three sources (Table 3) shows the risk of having breast cancer if an individual is exposed to a particular risk factor compared to the risk of having breast cancer if an individual is not exposed to the risk factor. The higher the relative risk then the greater the association between the risk factor and breast cancer.

Table 3: Factors that increase the relative risk for female breast cancer

<table>
<thead>
<tr>
<th>Factor</th>
<th>Source 1</th>
<th>Source 2</th>
<th>Source 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced age</td>
<td>&gt;10</td>
<td>&gt;4</td>
<td>&gt;4</td>
</tr>
<tr>
<td>Affluent country of residence</td>
<td>5</td>
<td>&gt;4</td>
<td>-</td>
</tr>
<tr>
<td>BRCA1 or BRCA2 gene mutation</td>
<td>-</td>
<td>&gt;4</td>
<td>&gt;4</td>
</tr>
<tr>
<td>High breast density for age on mammogram</td>
<td>5</td>
<td>&gt;4</td>
<td>&gt;4</td>
</tr>
<tr>
<td>Previous breast cancer</td>
<td>4-5</td>
<td>&gt;4</td>
<td>&gt;4</td>
</tr>
<tr>
<td>Previous atypical hyperplasia</td>
<td>&gt;4</td>
<td>2-3.99</td>
<td>&gt;4</td>
</tr>
<tr>
<td>High exposure to ionising radiation</td>
<td>3</td>
<td>1.25-1.99</td>
<td>2.1-4.0</td>
</tr>
<tr>
<td>First child after 40 years of age</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>First child after 29 years of age</td>
<td>-</td>
<td>1.25-1.99</td>
<td>1.1-2.0</td>
</tr>
<tr>
<td>Menarche before 11 years of age</td>
<td>3</td>
<td>*</td>
<td>1.1-2.0</td>
</tr>
<tr>
<td>Menopause after 54 years of age</td>
<td>2</td>
<td>1.25-1.99</td>
<td>1.1-2.0</td>
</tr>
<tr>
<td>Breast cancer in the one first degree relative</td>
<td>&gt;2</td>
<td>1.25-1.99</td>
<td>2.1-4.0</td>
</tr>
<tr>
<td>High BMI post-menopausal</td>
<td>2</td>
<td>1.25-1.99</td>
<td>1.1-2.0</td>
</tr>
<tr>
<td>In utero exposure to diethylstilbestrol</td>
<td>2</td>
<td>1.25-1.99</td>
<td>-</td>
</tr>
<tr>
<td>Current use of hormonal replacement therapy</td>
<td>1.66</td>
<td>1.25-1.99</td>
<td>1.1-2.0</td>
</tr>
<tr>
<td>Current use of oral contraceptives</td>
<td>1.2</td>
<td>1.25-1.99</td>
<td>1.1-2.0</td>
</tr>
<tr>
<td>One alcoholic drink daily</td>
<td>1.07</td>
<td>-</td>
<td>1.1-2.0</td>
</tr>
<tr>
<td>Three standard drinks daily</td>
<td>-</td>
<td>1.25-1.99</td>
<td>-</td>
</tr>
<tr>
<td>Nulliparous</td>
<td>-</td>
<td>1.25-1.99</td>
<td>1.1-2.0</td>
</tr>
<tr>
<td>High socio-economic status</td>
<td>2</td>
<td>-</td>
<td>1.1-2.0</td>
</tr>
<tr>
<td>Physical activity-2 or more hours of brisk</td>
<td>-</td>
<td>&lt;0.8</td>
<td>-</td>
</tr>
<tr>
<td>walking or equivalent per week (vs no activity)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Note: Relative risk is defined as the risk of having breast cancer if an individual is exposed to the risk factor compared to the risk of having breast cancer if an individual is not exposed to the risk factor. Therefore the higher the relative risk the greater the association between the risk factor and breast cancer.

6.1. Profile of breast cancer risk factors in ACT women.

6.1.1. Maternal age at first full-term pregnancy

ACT women have a consistently higher median maternal age at the first childbirth compared to the Australian population and the median age of ACT women giving birth has increased from 27 years in 1997 to 29 years in 2005 (Figure 32).

Figure 32: Median maternal age at first full-term pregnancy, ACT & Australia, 1997-2005

![Graph showing median maternal age at first full-term pregnancy, ACT and Australia, 1997-2005.](image)

Source: National Perinatal Data Collection; ACT Perinatal Data Collection.

6.1.2. Nulliparous (females who have never given birth)

Nulliparous is defined as the proportion of females who have reached the end of their childbearing years (15-44 years) and have not had any children. This can be derived for females aged 45 years and over from a census population which asks each woman the number of (live) babies she has ever had. The ACT has a higher proportion of women who are 45 years and over who have not given birth compared to the national average (ACT: 33%; Australia: 25% in 2000).31

Figure 33: Women who have not given birth, 45 years and over, by percentage, ACT & Australia, 2000

![Bar chart showing percentage of women who have not given birth, 45 years and over, by state and country.](image)

6.1.3. Socio-economic status

In 2006, the ACT had the highest median score and quartile values in the index of relative advantage and disadvantage (Figure 34). Studies have shown that socio-economic differentials exist in achieved parity, age at first birth, final childlessness, duration of breastfeeding, and possibly also age at menopause. Studies suggest that women of higher socio-economic status and with more education had lower fertility and later age at first birth, but a greater prevalence of childlessness, shorter duration of breastfeeding and later age at menopause.

Figure 34: Index of relative advantage & disadvantage, by state & territory, 2006

Source: ABS Socio-economic indexes for areas (SEIFA)-Technical paper. 2039.0.55.001.

6.1.4. Use of exogenous hormones

According to the National Health Survey 2004-05, ACT females reported a similar proportion of currently use of hormonal replacement therapy as Australian women in general (ACT: 7.5%, Australia: 6.1%).

6.1.5. Overweight and obesity

The National Health Survey 2007-08 results show that overweight and obesity were major health issues in the ACT and Australia. About 50.5 per cent of females were classed as overweight or obese in the ACT compared to 54.9 per cent nationally.

6.1.6. Alcohol intake

National Drug Strategy Household Survey conducted in 2007 shows that ACT women aged 14 years and over were significantly more likely to drink at levels considered to cause short-term harm compared to Australian women (ACT:34.3%, Aust:30.5%), but not at levels considered to cause long-term harm (ACT:11.1%, Aust 10.5%).
7. Treatment

7.1. The ACT and SE NSW Breast Cancer Treatment Group

The ACT and SE NSW Breast Cancer Treatment Group (BCTG) was established in 1995. The group comprises clinicians and other parties involved in the management of women with breast cancer in the ACT and SE NSW region. One of the BCTG key objectives is to facilitate the implementation of clinical practice guidelines for breast cancer in the ACT. In addition, this group aims at promoting research into current breast cancer treatment in the Canberra region.

The Group established the Breast Cancer Treatment Quality Assurance (BCTQA) project in 1997 for the purpose of auditing of breast cancer treatment in the ACT and SE NSW region. Data collected by this project have been administered by the BCTG’s Data Collection Sub-committee. All breast cancer treatment data presented in this report were extracted from the ACT and SE NSW BCTG Newsletter published in December 2008.37

7.2. Characteristics of breast cancer patients

From 1 July 1997 to 30 June 2008, 3,351 breast cancer patients (96% of all breast cancer patients who received treatment) from the ACT and surrounding SE NSW region agreed to include their information in the BCTQA project (Figure 35).

Figure 35: Treated breast cancer cases included in the Breast Cancer Treatment Quality Assurance Project, number, ACT & surrounding SE NSW region, 1 Jul 1997 to 30 June 2008


The majority of female breast cancer patients were post-menopausal (65%), and had an invasive cancer (88%) (Table 4). Only a very small proportion of these patients had distant metastases (1.6%) at the time of diagnosis. The median age at diagnosis of this cohort of patients was 57.2 years (range 22 to 95 years). A small number of men with breast cancer were included this cohort.
Table 4: Characteristics of breast cancer patients, ACT & SE NSW region, 1997-2008

<table>
<thead>
<tr>
<th></th>
<th>Number</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>3146</td>
<td>99.4</td>
</tr>
<tr>
<td>Male</td>
<td>20</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Menopausal status</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre</td>
<td>813</td>
<td>25.7</td>
</tr>
<tr>
<td>Post</td>
<td>2047</td>
<td>64.8</td>
</tr>
<tr>
<td>Peri</td>
<td>271</td>
<td>8.6</td>
</tr>
<tr>
<td>Unknown/Male</td>
<td>35</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive carcinoma</td>
<td>2790</td>
<td>88.1</td>
</tr>
<tr>
<td>Ductal carcinoma in situ</td>
<td>376</td>
<td>11.9</td>
</tr>
<tr>
<td><strong>Tumour extent</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distant metastases at diagnosis</td>
<td>50</td>
<td>1.6</td>
</tr>
<tr>
<td>Synchronous bilateral tumours</td>
<td>225</td>
<td>7.1</td>
</tr>
</tbody>
</table>


7.3. Method of detection and tumour size

Patient self examination (51%, N=1397) and BreastScreen program (30%, N=834) were the most common methods of detection of invasive breast cancer cases from 1997 to 2008 in ACT and SE NSW region (Figure 36).

Patient self detection was the predominant method of detection when tumours were over 10 mm. In the 11-20 mm category, both screening and patient self detection predominated. When tumours were small (0-10mm) most were detected by the BreastScreen program (50%). Screening by general practitioners did not detect large numbers of cases in any category.

Figure 36: Breast cancer patients by method of detection & tumour size, ACT & SE NSW region, 1997-2008

7.4. Surgical and adjuvant treatment

Data about treatment are presented for 2761 patients with invasive breast cancer and 363 with ductal carcinoma in situ (Figure 37). Breast conserving surgery was slightly higher in patients with ductal carcinoma in situ (DCIS) (53%) than for those with invasive disease (47%).

The principal purpose of adjuvant therapy is to kill any cancer cells that may have spread. Treatment is usually systemic i.e. substances are used that travel through the bloodstream, reaching and affecting cancer cells in the body. Adjuvant therapy for breast cancer involves chemotherapy or hormonal therapy, either alone or in combination. Radiation therapy sometimes is used as a local adjuvant treatment when it is given before or after a mastectomy.

Adjuvant treatment was provided for over 90 per cent of people with invasive breast cancer and 35% of those with DCIS. Adjuvant treatment was higher in cases who had breast conserving surgery.

Among the invasive cases who had mastectomy, chemotherapy (65%), and hormonal therapy (78%) were the common adjuvant treatments given. Radiotherapy as an adjuvant therapy was given to more than one-third of these patients (37%).

Among the invasive cases who had breast conserving surgery, radiotherapy (95%) and hormonal therapy (79%) were common adjuvant treatments given. Chemotherapy as an adjuvant therapy was received by 40% of these patients.

Among the ductal carcinoma in situ (DCIS) cases, adjuvant therapy was less commonly given compared to the invasive cases. About 48% of those who had breast conserving surgery and 21% of those who had mastectomy received adjuvant therapy.

Among the DCIS cases who had mastectomy, hormonal therapy (18%) was more commonly offered compared to other adjuvant therapies (chemotherapy: 5%; radiotherapy: 5%).

Among the DCIS cases who had breast conserving surgery, radiotherapy (31%) was more commonly offered compared to other adjuvant therapies.
### Figure 37: Types of treatment received by breast cancer patients, ACT & SE NSW region, 1997-2008

<table>
<thead>
<tr>
<th></th>
<th>Invasive breast cancer N=2761</th>
<th>Ductal carcinoma in situ N=363</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast conserving</strong></td>
<td>n=1288 (47%)</td>
<td>n=170 (47%)</td>
</tr>
<tr>
<td><strong>Mastectomy</strong></td>
<td>n=1473 (53%)</td>
<td>n=193 (53%)</td>
</tr>
<tr>
<td><strong>Radiotherapy</strong></td>
<td>n=1220 (95%)</td>
<td>n=60 (31%)</td>
</tr>
<tr>
<td><strong>Chemotherapy</strong></td>
<td>n=520 (40%)</td>
<td>n=955 (65%)</td>
</tr>
<tr>
<td><strong>Hormonal</strong></td>
<td>n=1012 (79%)</td>
<td>n=1150 (78%)</td>
</tr>
</tbody>
</table>


Notes: Forty-two patients who did not undergo surgery were excluded.
** These patients had contralateral invasive breast cancer.
8. Statistical definitions and methodology

Age-specific rates

Rate for specific age-groups. The numerator and denominator relate to the same age-group. Age-specific rates are calculated by dividing the number of cases occurring in each specified five-year age-group (and sex) by the corresponding population in the same age-group (and sex) and are expressed as an annual rate per 100,000 population.

Age-standardised rates (ASR)

Rates are adjusted for age to facilitate comparisons between populations that have different age structures, e.g. between youthful and ageing communities. In this report, direct standardisation is used, in which age-specific rates are used to calculate the number of cases that would have occurred if the population had the same age distribution as the Australian Standard Population 2001. This effectively removes the influence of age structure on the summary rate, which is described as the age standardised rate. The method can be used for both incidence and mortality calculations. This measure makes the incidence/mortality rate appropriate for the purpose of comparison with other Australian jurisdictions and over time.

Average annual percentage change (AAPC)

The average annual percentage change (AAPC) is the average yearly increase or decrease in incidence or mortality trends over the specified period, expressed as a percentage. Positive annual percentage change (APC) values indicate an increasing trend whilst negative APC values indicate a decreasing trend. A trend is taken to be statistically significant if the 95% confidence interval does not include zero.

AAPC values in this report were calculated using a statistical method called Joinpoint regression analysis or segmented regression, with a software, Joinpoint Regression Program 3.3.1, developed by the National Cancer Institute of the USA.39

The Joinpoint regression method is similar to the least square regression method. The Joinpoint method evaluates changing trends over successive segments over time. A Joinpoint is the point at which the linear segment changes significantly.

The program starts with the assumption of constant change over time (i.e. no joinpoint). Up to three joinpoints were tested in each model, depending on the number of years of data available and the stability of the yearly estimates. The trend line was tested against the statistical significance using a Monte Carlo Permutation method.

Crude rate

A crude rate (incidence/mortality) is the number of new cases/deaths in a population during a specific period (usually one year). A crude incidence/mortality rate is commonly expressed as a rate per 100,000 population.

Incidence

Cancer incidence is defined as the number of new cases of cancer in a population during a specific period (usually one year). Incidence is commonly expressed as a rate per 100,000 population.

Median age at diagnosis

A middle value of age at diagnosis, i.e. 50 per cent of cancer cases are diagnosed at an older age and 50 per cent are diagnosed at a younger age compared to the median age.

Mortality

Cancer mortality refers to deaths from cancer in a given population occurring in a specified period (usually one year). Similar to incidence, mortality is expressed as a rate (per 100,000 population). These cancers may have been diagnosed during or before the period in question. Cases for which a death certificate was the only source of notification (0.7%) and those diagnosed at post mortem (0.05%) are included.
Relative survival estimates

Relative survival ratio is the proportion of the observed survival rate to the expected survival rate expressed in percentage. Observed survival rate refers to cancer patients who would have survived to a certain time, usually five years for cancer, if the cancer they had was the only cause of death in the patient population.

Expected survival rate refers to expected rate of a group of people in the general population similar to the patient group with respect to race, sex, age and calendar period of observation. In this report, the expected survival rates were obtained from life tables of the general population of the ACT.

A relative survival estimate of 100% in this publication means that women with breast cancer would have the same survival expectations as the general population.

In this report, a method known as period approach was used to estimate the relative survival ratio. Survival time was calculated from the date of diagnosis to the date of death or follow-up on 31 December 2004. People whose death was the same as their date of diagnosis were excluded from analysis. Most of these cases were death certificate only (DCO) notifications. The traditional cohort method was used to estimate two different periods (diagnosis during 1995-1999; diagnosis during 2000-04) with follow up ending on 31 December 2006.

In contrast to the traditional cohort method of survival ratios, the period approach derives long-term survival estimates exclusively from the survival experience of patients within the most recent calendar period whereas the cohort method looks at how many people diagnosed in a certain year died later from their disease within a broad time frame. This approach includes many who died when treatments were not as sophisticated as they are now, and when screening was less likely to detect cancers earlier.

To estimate the 5-year survival of the period window (1 Jan 2000 - 31 Dec 2004), survival experience of cancer cases diagnosed between 1 Jan 1995 and 31 Dec 2004 is used. Using annual intervals, the following lists out contributions for each conditional estimate:

- First year with contributions from patients diagnosed 1999-2004;
- Second year with contributions from patients diagnosed 1998-2003;
- Third year with contributions from patients diagnosed 1997-2002;
- Fourth year with contributions from patients diagnosed 1996-2001; and
- Fifth year with contributions from patients diagnosed 1995-2000.

The period 5-year survival is then calculated by multiplying these interval survival probabilities. All statistical analyses were performed using Intercooled Stata 9.2. Period, hybrid and cohort approaches of relative survival estimates were calculated using Stata codes written by Paul Dickman, Enzo Coviello, and Michael Hills.38
9. References

32. Australian Bureau of Statistics. ABS Socio-economic indexes for areas - Technical paper. ABS Cat.no. 2039.0.55.00. Canberra: ABS.